Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
21,177,221
-
Share change
-
-4,322,725
-
Total reported value
-
$21,148,134
-
Put/Call ratio
-
26%
-
Price per share
-
$1.00
-
Number of holders
-
59
-
Value change
-
-$6,613,516
-
Number of buys
-
19
-
Number of sells
-
44
Institutional Holders of TCR2 THERAPEUTICS INC - COM (TCRR) as of Q4 2022
As of 31 Dec 2022,
TCR2 THERAPEUTICS INC - COM (TCRR) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,177,221 shares.
The largest 10 holders included
MPM ASSET MANAGEMENT LLC, BIOIMPACT CAPITAL LLC, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Newtyn Management, LLC, ACADIAN ASSET MANAGEMENT LLC, BlackRock Inc., BAKER BROS. ADVISORS LP, Artal Group S.A., and Redmile Group, LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.